Quantitation of interferon regulatory factor transcripts in patients with acute myeloid leukemia

Supriya Perambakam, Biaoru Li, Harvey Preisler

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Interferon regulatory factors IRF-1 and IRF-2, the two mutually antagonistic factors, fluctuate during the cell cycle and play an important role in normal and neoplastic growth processes. The relative levels of these two transcripts were analyzed in 5 normal and 43 acute myeloid leukemia (AML) bone marrow (BM) specimens by a semiquantitative RT-PCR method. IRF-1 and IRF-2 cDNA sequences were coamplified using primers that were designed to span regions of high homology between the genes. Each primer can anneal equally to both IRF-1 and IRF-2 sequences. Hence, the relative amount of amplified products from each cDNA species provides an estimation of proportional concentration of the RNA transcripts in the test sample. Results indicate expression of both the transcripts on all the leukemia and lymphoma cell lines tested, normal and AML BM. Significantly higher IRF-1:IRF-2 ratio was observed in normal as compared to AML BM (p = 0.007). There was no correlation with clinical factors such as FAB subtype. A single dose of amifostine or three daily doses of recombinant IL-4 were administered to 5 and 8 AML patients, respectively. The changes in the expression of these transcripts were studied prior to administration of the agent (d0) and after 3 days (d3). IL-4 treatment showed significant increase in the IRF-1:IRF-2 ratio in 4 of 8 patients (p = 0.05); amifostine treatment did not show any appreciable change.

Original languageEnglish (US)
Pages (from-to)346-351
Number of pages6
JournalCancer Investigation
Volume19
Issue number4
DOIs
StatePublished - Jun 21 2001

Fingerprint

Interferon Regulatory Factors
Acute Myeloid Leukemia
Amifostine
Bone Marrow
Interleukin-4
Complementary DNA
Interferon Regulatory Factor-1
Neoplastic Processes
Lymphoma
Cell Cycle
Leukemia
RNA
Cell Line
Polymerase Chain Reaction
Therapeutics
Growth
Genes

Keywords

  • AML
  • Amifostine
  • Bone marrow
  • IL-4
  • IRF-1
  • IRF-2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Quantitation of interferon regulatory factor transcripts in patients with acute myeloid leukemia. / Perambakam, Supriya; Li, Biaoru; Preisler, Harvey.

In: Cancer Investigation, Vol. 19, No. 4, 21.06.2001, p. 346-351.

Research output: Contribution to journalArticle

@article{e4bf9e43c3f94e689ee60e754fde336d,
title = "Quantitation of interferon regulatory factor transcripts in patients with acute myeloid leukemia",
abstract = "Interferon regulatory factors IRF-1 and IRF-2, the two mutually antagonistic factors, fluctuate during the cell cycle and play an important role in normal and neoplastic growth processes. The relative levels of these two transcripts were analyzed in 5 normal and 43 acute myeloid leukemia (AML) bone marrow (BM) specimens by a semiquantitative RT-PCR method. IRF-1 and IRF-2 cDNA sequences were coamplified using primers that were designed to span regions of high homology between the genes. Each primer can anneal equally to both IRF-1 and IRF-2 sequences. Hence, the relative amount of amplified products from each cDNA species provides an estimation of proportional concentration of the RNA transcripts in the test sample. Results indicate expression of both the transcripts on all the leukemia and lymphoma cell lines tested, normal and AML BM. Significantly higher IRF-1:IRF-2 ratio was observed in normal as compared to AML BM (p = 0.007). There was no correlation with clinical factors such as FAB subtype. A single dose of amifostine or three daily doses of recombinant IL-4 were administered to 5 and 8 AML patients, respectively. The changes in the expression of these transcripts were studied prior to administration of the agent (d0) and after 3 days (d3). IL-4 treatment showed significant increase in the IRF-1:IRF-2 ratio in 4 of 8 patients (p = 0.05); amifostine treatment did not show any appreciable change.",
keywords = "AML, Amifostine, Bone marrow, IL-4, IRF-1, IRF-2",
author = "Supriya Perambakam and Biaoru Li and Harvey Preisler",
year = "2001",
month = "6",
day = "21",
doi = "10.1081/CNV-100103129",
language = "English (US)",
volume = "19",
pages = "346--351",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Quantitation of interferon regulatory factor transcripts in patients with acute myeloid leukemia

AU - Perambakam, Supriya

AU - Li, Biaoru

AU - Preisler, Harvey

PY - 2001/6/21

Y1 - 2001/6/21

N2 - Interferon regulatory factors IRF-1 and IRF-2, the two mutually antagonistic factors, fluctuate during the cell cycle and play an important role in normal and neoplastic growth processes. The relative levels of these two transcripts were analyzed in 5 normal and 43 acute myeloid leukemia (AML) bone marrow (BM) specimens by a semiquantitative RT-PCR method. IRF-1 and IRF-2 cDNA sequences were coamplified using primers that were designed to span regions of high homology between the genes. Each primer can anneal equally to both IRF-1 and IRF-2 sequences. Hence, the relative amount of amplified products from each cDNA species provides an estimation of proportional concentration of the RNA transcripts in the test sample. Results indicate expression of both the transcripts on all the leukemia and lymphoma cell lines tested, normal and AML BM. Significantly higher IRF-1:IRF-2 ratio was observed in normal as compared to AML BM (p = 0.007). There was no correlation with clinical factors such as FAB subtype. A single dose of amifostine or three daily doses of recombinant IL-4 were administered to 5 and 8 AML patients, respectively. The changes in the expression of these transcripts were studied prior to administration of the agent (d0) and after 3 days (d3). IL-4 treatment showed significant increase in the IRF-1:IRF-2 ratio in 4 of 8 patients (p = 0.05); amifostine treatment did not show any appreciable change.

AB - Interferon regulatory factors IRF-1 and IRF-2, the two mutually antagonistic factors, fluctuate during the cell cycle and play an important role in normal and neoplastic growth processes. The relative levels of these two transcripts were analyzed in 5 normal and 43 acute myeloid leukemia (AML) bone marrow (BM) specimens by a semiquantitative RT-PCR method. IRF-1 and IRF-2 cDNA sequences were coamplified using primers that were designed to span regions of high homology between the genes. Each primer can anneal equally to both IRF-1 and IRF-2 sequences. Hence, the relative amount of amplified products from each cDNA species provides an estimation of proportional concentration of the RNA transcripts in the test sample. Results indicate expression of both the transcripts on all the leukemia and lymphoma cell lines tested, normal and AML BM. Significantly higher IRF-1:IRF-2 ratio was observed in normal as compared to AML BM (p = 0.007). There was no correlation with clinical factors such as FAB subtype. A single dose of amifostine or three daily doses of recombinant IL-4 were administered to 5 and 8 AML patients, respectively. The changes in the expression of these transcripts were studied prior to administration of the agent (d0) and after 3 days (d3). IL-4 treatment showed significant increase in the IRF-1:IRF-2 ratio in 4 of 8 patients (p = 0.05); amifostine treatment did not show any appreciable change.

KW - AML

KW - Amifostine

KW - Bone marrow

KW - IL-4

KW - IRF-1

KW - IRF-2

UR - http://www.scopus.com/inward/record.url?scp=0035009658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035009658&partnerID=8YFLogxK

U2 - 10.1081/CNV-100103129

DO - 10.1081/CNV-100103129

M3 - Article

C2 - 11405174

AN - SCOPUS:0035009658

VL - 19

SP - 346

EP - 351

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 4

ER -